20 Years of RA Data: First-Line Biologic & Targeted Synthetic DMARD Trends

Reference

1. Ertenli AI, Kalyoncu U, Karadag O, et al. Trends in the choice of first biologic and targeted synthetic DMARD in rheumatoid arthritis patients: 20-years journey of HUR-BIO real-life registry [abstract AB0200]. Ann Rheum Dis. 2021; 80(suppl 1):1124.2–1124.